

**Appendix X. Author Relationships With Industry and Other Entities (COMPREHENSIVE)—2019 ACC Expert Consensus Decision Pathway: Heart Failure Predischarge Risk Assessment**

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Steven M. Hollenberg ( <i>Chair</i> )	Hackensack Meridian School of Medicine at Seton Hall University—Professor of Medicine	None	None	None	None	None	None
Lynne Warner Stevenson ( <i>Vice-Chair</i> )	Vanderbilt University School of Medicine—Professor of Medicine	<ul style="list-style-type: none"> <li>• NHLBI (n)</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Abbott (n)</li> <li>• NHLBI-INTERMACS (Co-PI) (n)</li> <li>• Novartis (n)</li> </ul>	<ul style="list-style-type: none"> <li>• Abbott</li> <li>• NHLBI (n)</li> </ul>	None
Tariq Ahmad	Yale University School of Medicine—Assistant Professor of Medicine	<ul style="list-style-type: none"> <li>• Amgen</li> </ul>	<ul style="list-style-type: none"> <li>• Novartis (s)</li> </ul>	None	None	None	None
Vaibhav J. Amin	Piedmont Heart Institute Newnan	None	None	None	None	None	None
Biykem Bozkurt	Baylor College of Medicine—Professor of Medicine	<ul style="list-style-type: none"> <li>• Bristol Myers Squibb</li> <li>• scPharmaceuticals, Inc</li> <li>• LAntheus Medical Imaging</li> <li>• Bayer Health Care Pharmaceuticals</li> <li>• Respicardia</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Liva Nova, Anthem Trial (DSMB)</li> <li>• Abbott Guide HF Trial (CEC)</li> <li>• DSMC</li> </ul>	<ul style="list-style-type: none"> <li>• Novartis‡</li> <li>• Circulation (n)</li> </ul>	None
Javed Butler	University of Mississippi—Professor of Medicine	<ul style="list-style-type: none"> <li>• Adrenomed</li> <li>• AstraZeneca</li> <li>• Bayer (s)</li> <li>• Berlin Cures</li> <li>• Boehringer Ingelheim (s)</li> <li>• Boston Scientific</li> <li>• CVRx</li> <li>• G3 Pharmaceuticals</li> <li>• Janssen (s)</li> <li>• Luitpold</li> </ul>	<ul style="list-style-type: none"> <li>• Novartis (s)</li> </ul>	None	<ul style="list-style-type: none"> <li>• Amgen (DSMB)</li> <li>• Bristol-Myers Squibb (DSMB)</li> <li>• European Union (s)</li> <li>• NIH (s)</li> </ul>	<ul style="list-style-type: none"> <li>• AHA (s)</li> <li>• American Heart Journal (n)</li> <li>• European Journal of Heart Failure (n)</li> <li>• HFSA (n)</li> <li>• JACC (n)</li> <li>• JACC Heart Failure (n)</li> <li>• Medscape</li> </ul>	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
		Pharmaceuticals <ul style="list-style-type: none"> <li>• Medtronic</li> <li>• Merck (s)</li> <li>• Novartis (s)</li> <li>• Relypsa (s)</li> <li>• Roche</li> <li>• Sanofi-Aventis</li> <li>• Stealth Peptide</li> <li>• Vifor (s)</li> <li>• ZS Pharma</li> </ul>				<ul style="list-style-type: none"> <li>• NIH‡</li> </ul>	
Leslie L. Davis	University of North Carolina Chapel Hill—Associate Professor of Nursing	None	None	None	None	<ul style="list-style-type: none"> <li>• AANP</li> <li>• ASH</li> </ul>	None
Mark H. Drazner	UT Southwestern Medical Center—Clinical Chief of Cardiology; Medical Director of the Heart Failure, LVAD, and Cardiac Transplantation Program; Professor of Medicine	None	None	None	<ul style="list-style-type: none"> <li>• AHA (s)</li> </ul>	<ul style="list-style-type: none"> <li>• AHA (s)</li> <li>• Alnylam‡</li> <li>• DCRI/Otsuka American Pharmaceutical‡</li> <li>• NHLBI‡</li> <li>• St. Jude (s)</li> <li>• St. Lukes’ Hospital (KC) ‡</li> <li>• Trevena (s)</li> <li>• UptoDate</li> </ul>	None
James N. Kirkpatrick	University of Washington Medical Center—Associate Professor of Medicine, Division of Cardiology and Department of Bioethics and Humanities; Director of Echocardiography; Ethics Committee Chair	None	None	None	<ul style="list-style-type: none"> <li>• ASE Site for WASE study (PI) (n)</li> <li>• NASA</li> <li>• University of Washington Division of Cardiology Kaylor Family Research Award (s)</li> </ul>	<ul style="list-style-type: none"> <li>• ASE (n)</li> <li>• Christian Medical and Dental Associations (n)</li> <li>• HRS (n)</li> <li>• Journal of the American Society of Echocardiography (n)</li> <li>• Mount Sinai Medical Center (n)</li> <li>• NHLBI (n)</li> </ul>	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Pamela N. Peterson	University of Colorado Denver, Anschutz Medical Campus—Professor of Medicine; Denver Health Medical Center	•	None	None	None	AHA (s)	None
Brent N. Reed	University of Maryland School of Pharmacy— Associate Professor, Pharmacy Practice & Science; Program Director, PGY2 Cardiology Pharmacy Residency Program, Department of Pharmacy Practice & Science	None	None	None	None	None	None
Christopher L. Roy	Brigham and Women's Hospital—Director of Hospital Medicine; Harvard Medical School—Assistant Professor of Medicine	None	None	None	None	None	None
Alan B. Storrow	Vanderbilt University School of Medicine—Vice-Chairman for Research and Academic Affairs; Associate Professor of Emergency Medicine	<ul style="list-style-type: none"> <li>• Alere</li> <li>• Siemens (s)</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Trevena (DSMB)</li> </ul>	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq \$5,000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

n- No financial benefit. [insert symbol prior to publication]

s - Significant relationship [insert symbol prior to publication]

‡ Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.

AANP=American Association of Nurse Practitioners; AHA=American Heart Association; ASE=American Society of Echocardiography; ASH=American Society of Hypertension; Co-PI=Co-Investigator; HFSA=Heart Failure Society of America; HRS=Heart Rhythm Society; JACC=Journal of the American College of Cardiology; NASA=National Atmospheric and Space Administration; NHLBI= National Heart, Lung, and Blood Institute; NIH=National Institutes of Health; PI=Principal Investigator.